{
    "038.F": {
        "short_name": "NOVOCURE LTD",
        "long_name": "NovoCure Limited",
        "summary": "NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Jersey",
        "state": null,
        "city": "Saint Helier",
        "zipcode": "JE2 4UF",
        "website": "http://www.novocure.com",
        "market_cap": "Large Cap"
    },
    "NVCR": {
        "short_name": "NovoCure Limited",
        "long_name": "NovoCure Limited",
        "summary": "NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Jersey",
        "state": null,
        "city": "Saint Helier",
        "zipcode": "JE2 4UF",
        "website": "http://www.novocure.com",
        "market_cap": "Large Cap"
    }
}